Abstract:Lymphangioleiomyomatosis (LAM) is a diffuse cystic lung disease. There are two main types of LAM: sporadic, and LAM associated with the tuberous sclerosis complex (TSC), which is caused by mutations in the TSC1 and TSC2 genes. LAM is characterised by cystic lung disease resulting in progressive dyspnoea, renal angiomyolipomas and lymphatic complications. Pneumothorax occurs frequently (70%) and definitive management with pleurodesis is recommended as the risk of recurrence is high. Characteristic thin-walled cysts are seen on computed tomography and the presence of elevated serum levels of a vascular endothelial growth factor-D has good diagnostic specificity. Currently, no single clinical or serological factor has been shown to predict prognosis. However, over the past decade, significant advances in our understanding of the pathophysiology of LAM has led to improved recognition of this rare disease and identification of treatment options. Mechanistic target of rapamycin inhibitors slow the rate of lung function decline and can resolve chylous effusion and regress angiomyolipomas. Life expectancy in patients with LAM is favourable, with a mean transplant-free survival >20 years from the time of diagnosis. Continued advances in understanding the molecular basis of LAM will lead to improved therapeutic targets and the development of more robust prognostic indicators. Educational aims To illustrate the clinical features, common presentations and radiological features of LAM To outline the diagnostic approach to LAM, including the role of VEGF-D To review the current prognostic indicators in LAM, and outline the impact of lung function, hormonal status, VEGF-D and clinical presentation on outcome To inform clinicians on the management options for LAM both pharmacological and nonpharmacological

Recent Progress in Study of Pulmonary Lymphangioleiomyomatosis

Advance in diagnosis and treatment of pulmonary lymphangitic carcinomatosis

Pulmonary Lmphangioleiomyomatosis :A Cinicpathological Aalysis and Review of Literature

A Case of Tuberous Sclerosis Complex Associated Lymphangioleiomyomatosis and Review of Literatures

Clinicopathological analysis of pulmonary lymphangioleiomyomatosis:a report of 7 cases

Clinical Analysis of Patients with Pulmonary Lymphangioleiomyomatosis (PLAM) in Mainland China

Pulmonary Lymphangioleiomyomatosis Accompanied with Renal Angiomyolipoma:Report of a Case and Literature Review

Research Progress in Treatment of Peripheral T-cell Lymphoma

Role of estrogen in pulmonary lymphangioleiomyomatosis

Possible Novel Therapeutic Targets in Lymphangioleiomyomatosis Treatment

Clinical Analysis of 48 Cases with Pulmonary Lymphangioleiomyomatosis:A Report of Three Cases and Review of Domestic Literatures Published in the Past Ten Years

Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma from Chinese Patients.

The Novel KLF4/PLAC8 Signaling Pathway Regulates Lung Cancer Growth.

Omics research in lymphangioleiomyomatosis: status and challenges

Research progress on primary pulmonary lymphoma

Diffuse Pulmonary Lymphangiomatosis: a Case Report with Literature Review.

Lymphangioleiomyomatosis: a clinical review

Pulmonary lymphangiomatosis: insights into an ultra-rare disease

Identification of common genetic features and pathways involved in pulmonary lymphangioleiomyomatosis and ER-positive breast cancer

Pulmonary lymphangioleiomyomatosis (LAM): A literature overview and case report

Novel developments in the study of estrogen in the pathogenesis and therapeutic intervention of lymphangioleiomyomatosis